Synthesis of selective SRPK-1 inhibitors

Novel tricyclic quinoxaline derivatives

Zsolt Székelyhidi, János Pató, Frigyes Wáczek, Péter Bánhegyi, Bálint Hegymegi-Barakonyi, Dániel Eros, György Mészáros, F. Hollósy, Doris Hafenbradl, Sabine Obert, Bert Klebl, G. Kéri, L. Őrfi

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

SR protein-specific kinase-1 (SRPK-1) has been identified as a validated target for hepatitis B virus (HBV). A series of novel tricyclic quinoxaline derivatives was designed and synthesised as potential kinase inhibitory antiviral agents and was found to be active and selective for SRPK-1 kinase. Most of these novel compounds have drug-like properties according to experimentally determined Log P and Log S values.

Original languageEnglish
Pages (from-to)3241-3246
Number of pages6
JournalBioorganic and Medicinal Chemistry Letters
Volume15
Issue number13
DOIs
Publication statusPublished - Jul 1 2005

Fingerprint

Quinoxalines
Protein Kinases
Phosphotransferases
Derivatives
Hepatitis B virus
Antiviral Agents
Proteins
Viruses
Pharmaceutical Preparations

Keywords

  • Kinase inhibitor
  • Quinoxaline
  • SRPK-1

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Organic Chemistry
  • Drug Discovery
  • Pharmaceutical Science

Cite this

Székelyhidi, Z., Pató, J., Wáczek, F., Bánhegyi, P., Hegymegi-Barakonyi, B., Eros, D., ... Őrfi, L. (2005). Synthesis of selective SRPK-1 inhibitors: Novel tricyclic quinoxaline derivatives. Bioorganic and Medicinal Chemistry Letters, 15(13), 3241-3246. https://doi.org/10.1016/j.bmcl.2005.04.064

Synthesis of selective SRPK-1 inhibitors : Novel tricyclic quinoxaline derivatives. / Székelyhidi, Zsolt; Pató, János; Wáczek, Frigyes; Bánhegyi, Péter; Hegymegi-Barakonyi, Bálint; Eros, Dániel; Mészáros, György; Hollósy, F.; Hafenbradl, Doris; Obert, Sabine; Klebl, Bert; Kéri, G.; Őrfi, L.

In: Bioorganic and Medicinal Chemistry Letters, Vol. 15, No. 13, 01.07.2005, p. 3241-3246.

Research output: Contribution to journalArticle

Székelyhidi, Z, Pató, J, Wáczek, F, Bánhegyi, P, Hegymegi-Barakonyi, B, Eros, D, Mészáros, G, Hollósy, F, Hafenbradl, D, Obert, S, Klebl, B, Kéri, G & Őrfi, L 2005, 'Synthesis of selective SRPK-1 inhibitors: Novel tricyclic quinoxaline derivatives', Bioorganic and Medicinal Chemistry Letters, vol. 15, no. 13, pp. 3241-3246. https://doi.org/10.1016/j.bmcl.2005.04.064
Székelyhidi Z, Pató J, Wáczek F, Bánhegyi P, Hegymegi-Barakonyi B, Eros D et al. Synthesis of selective SRPK-1 inhibitors: Novel tricyclic quinoxaline derivatives. Bioorganic and Medicinal Chemistry Letters. 2005 Jul 1;15(13):3241-3246. https://doi.org/10.1016/j.bmcl.2005.04.064
Székelyhidi, Zsolt ; Pató, János ; Wáczek, Frigyes ; Bánhegyi, Péter ; Hegymegi-Barakonyi, Bálint ; Eros, Dániel ; Mészáros, György ; Hollósy, F. ; Hafenbradl, Doris ; Obert, Sabine ; Klebl, Bert ; Kéri, G. ; Őrfi, L. / Synthesis of selective SRPK-1 inhibitors : Novel tricyclic quinoxaline derivatives. In: Bioorganic and Medicinal Chemistry Letters. 2005 ; Vol. 15, No. 13. pp. 3241-3246.
@article{9719f1383cd847d29f22da24eeea3dd7,
title = "Synthesis of selective SRPK-1 inhibitors: Novel tricyclic quinoxaline derivatives",
abstract = "SR protein-specific kinase-1 (SRPK-1) has been identified as a validated target for hepatitis B virus (HBV). A series of novel tricyclic quinoxaline derivatives was designed and synthesised as potential kinase inhibitory antiviral agents and was found to be active and selective for SRPK-1 kinase. Most of these novel compounds have drug-like properties according to experimentally determined Log P and Log S values.",
keywords = "Kinase inhibitor, Quinoxaline, SRPK-1",
author = "Zsolt Sz{\'e}kelyhidi and J{\'a}nos Pat{\'o} and Frigyes W{\'a}czek and P{\'e}ter B{\'a}nhegyi and B{\'a}lint Hegymegi-Barakonyi and D{\'a}niel Eros and Gy{\"o}rgy M{\'e}sz{\'a}ros and F. Holl{\'o}sy and Doris Hafenbradl and Sabine Obert and Bert Klebl and G. K{\'e}ri and L. Őrfi",
year = "2005",
month = "7",
day = "1",
doi = "10.1016/j.bmcl.2005.04.064",
language = "English",
volume = "15",
pages = "3241--3246",
journal = "Bioorganic and Medicinal Chemistry Letters",
issn = "0960-894X",
publisher = "Elsevier Limited",
number = "13",

}

TY - JOUR

T1 - Synthesis of selective SRPK-1 inhibitors

T2 - Novel tricyclic quinoxaline derivatives

AU - Székelyhidi, Zsolt

AU - Pató, János

AU - Wáczek, Frigyes

AU - Bánhegyi, Péter

AU - Hegymegi-Barakonyi, Bálint

AU - Eros, Dániel

AU - Mészáros, György

AU - Hollósy, F.

AU - Hafenbradl, Doris

AU - Obert, Sabine

AU - Klebl, Bert

AU - Kéri, G.

AU - Őrfi, L.

PY - 2005/7/1

Y1 - 2005/7/1

N2 - SR protein-specific kinase-1 (SRPK-1) has been identified as a validated target for hepatitis B virus (HBV). A series of novel tricyclic quinoxaline derivatives was designed and synthesised as potential kinase inhibitory antiviral agents and was found to be active and selective for SRPK-1 kinase. Most of these novel compounds have drug-like properties according to experimentally determined Log P and Log S values.

AB - SR protein-specific kinase-1 (SRPK-1) has been identified as a validated target for hepatitis B virus (HBV). A series of novel tricyclic quinoxaline derivatives was designed and synthesised as potential kinase inhibitory antiviral agents and was found to be active and selective for SRPK-1 kinase. Most of these novel compounds have drug-like properties according to experimentally determined Log P and Log S values.

KW - Kinase inhibitor

KW - Quinoxaline

KW - SRPK-1

UR - http://www.scopus.com/inward/record.url?scp=20444383142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20444383142&partnerID=8YFLogxK

U2 - 10.1016/j.bmcl.2005.04.064

DO - 10.1016/j.bmcl.2005.04.064

M3 - Article

VL - 15

SP - 3241

EP - 3246

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

SN - 0960-894X

IS - 13

ER -